Literature DB >> 402107

Interferon induction in cynomolgus and rhesus monkey after repeated doses of a modified polyriboinosinic-polyribocytidylic acid complex.

M L Sammons, E L Stephen, H B Levy, S Baron, D E Hilmas.   

Abstract

Serum interferon activity was determined in 12 cynomolgus and 12 rhesus monkeys injected intravenously once daily for 10 days with from 0.1 to 6.0 mg of a stabilized polyriboinosinic acid . polyribocytidylic acid complex per kg, composed of polyriboinosinic acid . polyribocytidylic acid, poly-1-lysine, and carboxymethylcellulose [poly(ICLC)]. Interferon activity was detected 2 h after the first injection, with maximum activity occurring 8 h after the second injection. A period of hyporesponsiveness occurred after the third injection of poly(ICLC) in all monkeys and lasted until the sixth injection in the rhesus monkeys, when interferon activity again became more elevated. The delayed rebound was not as apparent in cynomolgus monkeys. Rhesus monkeys injected with 6 mg/kg did not exhibit serious side effects.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 402107      PMCID： PMC351921          DOI： 10.1128/AAC.11.1.80

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Hyporeactivity of infection: potential limitation to therapeutic use of interferon-inducing agents.

Authors:  D A Stringfellow; L A Glasgow
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

2.  The effect of interferon, interferon inducers or interferon induced virus resistance on subsequent interferon production.

Authors:  S A Margolis; H Oie; H B Levy
Journal:  J Gen Virol       Date:  1972-05       Impact factor: 3.891

3.  Evaluation of an interferon inducer in viral respiratory disease.

Authors:  D A Hill; S Baron; J C Perkins; M Worthington; J E Van Kirk; J Mills; A Z Kapikian; R M Chanock
Journal:  JAMA       Date:  1972-02-28       Impact factor: 56.272

4.  Semi-micro, dye-binding assay for rabbit interferon.

Authors:  J A Armstrong
Journal:  Appl Microbiol       Date:  1971-04

5.  Studies on poly I:C toxicity in experimental animals.

Authors:  E R Homan; R P Zendzian; L D Schott; H B Levy; R H Adamson
Journal:  Toxicol Appl Pharmacol       Date:  1972-12       Impact factor: 4.219

6.  The interferon refractory state: in vivo and in vitro studies of its mechanism.

Authors:  E C Borden; F A Murphy
Journal:  J Immunol       Date:  1971-01       Impact factor: 5.422

7.  Polyriboinosinic-polyribocytidylic acid-induced interferons in calves.

Authors:  B D Rosenquist
Journal:  Am J Vet Res       Date:  1971-01       Impact factor: 1.156

8.  Kinetics of serum interferon response in mice after single and multiple injections of polyI-poly C.

Authors:  C E Buckler; H G DuBuy; M L Johnson; S Baron
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

9.  The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein.

Authors:  E C Borden; E V Prochownik; W A Carter
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

10.  A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates.

Authors:  H B Levy; G Baer; S Baron; C E Buckler; C J Gibbs; M J Iadarola; W T London; J Rice
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226
View more
  11 in total

Review 1.  The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.

Authors:  A Sally Davis; Jeffery K Taubenberger; Mike Bray
Journal:  Antiviral Res       Date:  2015-03-05       Impact factor: 5.970

2.  Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.

Authors:  B J Giantonio; H Hochster; R Blum; P H Wiernik; G R Hudes; J Kirkwood; D Trump; M M Oken
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Systemic metabolic alterations associated with repeated injections of a modified polyriboinosinic-polyribocytidylic acid complex.

Authors:  M C Powanda; M L Sammons; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

4.  Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine.

Authors:  D G Harrington; C L Crabbs; D E Hilmas; J R Brown; G A Higbee; F E Cole; H B Levy
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

5.  Variations in the contribution of induced interferon and adjuvanticity to the antiviral effect of different polyinosinic acid . polycytidylic acid formulations in mice infected with encephalomyocarditis virus.

Authors:  N Stebbing; I J Lindley; K M Dawson
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

6.  Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.

Authors:  B G Gatmaitan; R C Legaspi; H B Levy; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

7.  Modified polyriboinosinic-polyribocytidylic acid complex: modulation of toxicity for rabbits by alterations in components.

Authors:  B G Gatmaitan; H B Levy; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

8.  Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice.

Authors:  Hussein Sultan; Juan Wu; Takumi Kumai; Andres M Salazar; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2018-04-25       Impact factor: 6.968

9.  Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.

Authors:  Christiane Stahl-Hennig; Martin Eisenblätter; Edith Jasny; Tamara Rzehak; Klara Tenner-Racz; Christine Trumpfheller; Andres M Salazar; Klaus Uberla; Karen Nieto; Jürgen Kleinschmidt; Reiner Schulte; Lutz Gissmann; Martin Müller; Anna Sacher; Paul Racz; Ralph M Steinman; Mariagrazia Uguccioni; Ralf Ignatius
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

10.  Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.

Authors:  Karen A O Martins; Jesse T Steffens; Sean A van Tongeren; Jay B Wells; Alison A Bergeron; Samuel P Dickson; John M Dye; Andres M Salazar; Sina Bavari
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.